Stock Events

Stock Events

Sol-Gel Technologies 

€63.5
15
-€4-5.93% Today

Statistics

Day High
63.5
Day Low
63.5
52W High
82
52W Low
0.3
Volume
-
Avg. Volume
-
Mkt Cap
176.91M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

8MayExpected
Q2 2024
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-3.2
-0.74
1.71
4.17
Expected EPS
-1.84
Actual EPS
N/A

Financials

-93.11%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
21.73MRevenue
-20.23MNet Income

Analyst Ratings

83.47Average Price Target
The highest estimate is 83.47.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 4SG.F. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Amneal Pharmaceuticals
AMRX
Mkt Cap4B
Amneal Pharmaceuticals, Inc. produces generic and specialty pharmaceutical products, including dermatological treatments, which compete with Sol-Gel's dermatology product line.
ANI Pharmaceuticals
ANIP
Mkt Cap1.78B
ANI Pharmaceuticals, Inc. develops, manufactures, and markets branded and generic prescription pharmaceuticals, in direct competition with Sol-Gel's pharmaceutical products.
Collegium Pharmaceutical
COLL
Mkt Cap1.15B
Collegium Pharmaceutical, Inc. is focused on developing and commercializing pain management and other products, competing in the same therapeutic areas as Sol-Gel.
Journey Medical
DERM
Mkt Cap171.94M
Dermira, Inc. focuses on advancing new therapies in dermatology, directly competing with Sol-Gel Technologies in the dermatological market.
Johnson & Johnson
JNJ
Mkt Cap574.66B
Johnson & Johnson, through its Janssen Pharmaceuticals segment, develops and markets pharmaceutical products for various therapeutic areas, including dermatology, competing with Sol-Gel's offerings.
Merck
MRK
Mkt Cap300.2B
Merck & Co., Inc. offers prescription medicines, vaccines, biologic therapies, and animal health products, including treatments in dermatology and acute pain, competing with Sol-Gel.
Pfizer
PFE
Mkt Cap153.13B
Pfizer Inc. is involved in the discovery, development, manufacture, and sale of healthcare products, including those for dermatological conditions, competing with Sol-Gel.
Teva- Pharmaceutical Industries
TEVA
Mkt Cap36.77B
Teva Pharmaceutical Industries Limited specializes in generic and specialty medicines, including dermatology, directly competing with Sol-Gel's product range.

About

Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel, China, Switzerland, Canada, the United States and internationally. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat olmsted syndrome. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
Show more...
CEO
Mr. Eyal Ben-Or
Employees
28
Country
Israel
ISIN
IL0011417206
WKN
000A2JDHD

Listings

STU
DE
4SG.STU
F
DE
4SG.F
XNAS
US
SLGL
BOATS
BOATS
SLGL.BOATS

0 Comments

Share your thoughts

FAQ

What is Sol-Gel Technologies stock price today?▼
The current price of 4SG.F is €63.5 EUR — it has decreased by -5.93% in the past 24 hours. Watch Sol-Gel Technologies stock price performance more closely on the chart.
What is Sol-Gel Technologies stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Sol-Gel Technologies stocks are traded under the ticker 4SG.F.
Is Sol-Gel Technologies stock price growing?▼
4SG.F stock has risen by +2.42% compared to the previous week, the month change is a +0% rise, over the last year Sol-Gel Technologies has showed a +18,042.86% increase.
What is Sol-Gel Technologies market cap?▼
Today Sol-Gel Technologies has the market capitalization of 176.91M
When is the next Sol-Gel Technologies earnings date?▼
Sol-Gel Technologies is going to release the next earnings report on May 08, 2026.
What were Sol-Gel Technologies earnings last quarter?▼
4SG.F earnings for the last quarter are 0.34 EUR per share, whereas the estimation was 0.34 EUR resulting in a +0% surprise. The estimated earnings for the next quarter are N/A EUR per share.
What is Sol-Gel Technologies revenue for the last year?▼
Sol-Gel Technologies revenue for the last year amounts to 21.73M EUR.
What is Sol-Gel Technologies net income for the last year?▼
4SG.F net income for the last year is -20.23M EUR.
How many employees does Sol-Gel Technologies have?▼
As of April 17, 2026, the company has 28 employees.
In which sector is Sol-Gel Technologies located?▼
Sol-Gel Technologies operates in the Health & Wellness sector.
When did Sol-Gel Technologies complete a stock split?▼
The last stock split for Sol-Gel Technologies was on May 05, 2025 with a ratio of 1:10.
Where is Sol-Gel Technologies headquartered?▼
Sol-Gel Technologies is headquartered in Ness Ziona, Israel.